キナーゼ関連論文

2024

• npj Precision Oncology, February 2024, 46
  A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
  Mai Suzuki, Ken Uchibori, Tomoko Oh-hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, Yusuke Kawase, Mikako Shirouzu, Yasushi Okuno, Makoto Nishio, Naoya Fujita & Ryohei Katayama

2022

• Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology, September 2022, 81 (13_Supplement)
  Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
  Jeffrey J. Kooijman1, Wilhelmina E. van Riel1, Jelle Dylus1, Martine B. W. Prinsen2†, Yvonne Grobben1, Tessa J. J. de Bitter1, Antoon M. van Doornmalen1, Janneke J. T. M. Melis1, Joost C. M. Uitdehaag2†, Yugo Narumi3, Yusuke Kawase3, Jeroen A. D. M. de Roos1, Nicole Willemsen-Seegers1 and Guido J. R. Zaman1*

2018

• Molecular Cancer Therapeutics, October 2018
  Combined cellular and biochemical profiling to identify predictive drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017
  Joost C.M. Uitdehaag, Jeffrey J. Kooijman, Jeroen A.D.M. de Roos, Martine B.W. Prinsen, Jelle Dylus, Nicole Willemsen-Seegers, Yusuke Kawase, Masaaki Sawa, Jos de Man, Suzanne J.C. van Gerwen, Rogier C. Buijsman, and Guido J.R. Zaman

2017

• Journal of Molecular Biology, February 2017, 429, Issue 4, 574-586
  Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.
  Willemsen-Seegers N1, Uitdehaag JCM1, Prinsen MBW1, de Vetter JRF1, de Man J1, Sawa M2, Kawase Y2, Buijsman RC1, Zaman GJR3.

2016

• Molecular Cancer Therapeutics, December 2016, 15, 12、3097-3109
  Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors
  Joost C.M. Uitdehaag, Jeroen A.D.M. de Roos, Martine B.W. Prinsen, Nicole Willemsen-Seegers, Judith R.F. de Vetter, Jelle Dylus, Antoon M. van Doornmalen, Jeffrey Kooijman, Masaaki Sawa, Suzanne J.C. van Gerwen, Jos de Man, Rogier C. Buijsman, and Guido J.R. Zaman

2014

• PLOS ONE, March 2014, 9, Issue 3, e92146
  Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use
  Joost C. M. Uitdehaag, Jeroen A. D. M. de Roos, Antoon M. van Doornmalen, Martine B. W. Prinsen, Jos de Man, Yoshinori Tanizawa, Yusuke Kawase, Kohichiro Yoshino, Rogier C. Buijsman, Guido J. R. Zaman
  Presented in Collaboration with NRTC
• Journal of Biomolecular Screening, March 2014, vol. 19 no. 3, 453-461
  Quick Evaluation of Kinase Inhibitors by Surface Plasmon Resonance Using Single-Site Specifically Biotinylated Kinases
  Daisuke Kitagawa, Masaki Gouda, Yasuyuki Kirii
  * For a PDF copy, please contact us at info@carnabio.com.

2012

• Journal of Biochemistry, January 2012, VOL. 151 (1), 47-55
  Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase
  Kitagawa D, Gouda M, Kirii Y, Sugiyama N, Ishihama Y, Fujii I, Narumi Y, Akita K, Yokota K
  * For a PDF copy, please contact us at info@carnabio.com.
• Genes to Cells, December 2012, VOL. 18, Issue 1, (Article first published online: 26 DEC 2012)
  Activity-based kinase profiling of approved tyrosine kinase inhibitors
  Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, Akita K, Kirii Y
  * For a PDF copy (3MB), please contact us at info@carnabio.com.

2009

• Currrent Neurovascular Research, August 2009, VOL. 6, Issue 3, 140-147
  CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor-alpha converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo.
  Chikaraishi Y, Shimazawa M, Yokota K, Yoshino K, Hara H.

2008

• Drug Design, Development and Therapy, November 2008, VOL. 2008:2, 255-264
  Drug design with Cdc7 kinase: potential cancer therapy target
  Masaaki Sawa, Hisao Masai*
  * Genome Dynamics Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
• Mini-Reviews in Medicinal Chemistry, October 2008, VOL. 8, Issue 12, 1291-1297
  Strategies for the Design of Selective Protein Kinase Inhibit
  Masaaki Sawa
• SCREENING, February 2008, VOL. 2/2008, 15-17
  Kinase Assay Development - A Strategy for Comprehensive Kinase Profiling for Drug Discovery
  Masaki Gouda

Split Luciferase /Protein-Protein Interactions

2019

• Scientific Reports, 9, Article number: 636 (2019) , 24 January 2019
  Development of Highly Sensitive Biosensors of RAF Dimerization in Cells
  Kyoko Miyamoto, Masaaki Sawa

2018

• Cytotechnology, PMID: 30112660
  A luciferase complementation assay system using transferable mouse artificial chromosomes to monitor protein-protein interactions mediated by G protein-coupled receptors.
  N. Uno, T. Fujimoto, S. Komoto, G. Kurosawa, M. Sawa, T. Suzuki, Y. Kazuki, M. Oshimura

2016

• Pharmacological Research, 114, 13-26 (2016). PMID: 27751876
  Label-free versus conventional cellular assays: functional investigations on the human histamine H1 receptor
  S. Lieb, T. Littmann, N. Plank, J. Felixberger, M. Tanaka, T. Schafer, S. Krief, S. Elz,
  K. Friedland, G. Bernhardt, J. Wegener, T. Ozawa and A. Buschauer
• Methods in Molecular Biology, 1461, 195-202 (2016). PMID: 27424906
  Live Cell Bioluminescence Imaging in Temporal Reaction of G Protein-Coupled Receptor for High-Throughput Screening and Analysis.
  M. Hattori and T. Ozawa

2015

• Methods in Molecular Biology
  Live Cell Bioluminescence Imaging in Temporal Reaction of G Protein-Coupled Receptor for High-Throuhput Screening and Analysis.
  M. Hattori and T. Ozawa
• Journal of Pharmacology and Experimental Therapeutics
  Recruitment of β-Arrestin 1 and 2 to the β2-Adrenoceptor: Analysis of 65 Ligands
  T. Littmann, M. Gottle, M.T. Reinartz, S. Kalble, I. W. Wainer, T. Ozawa, R. Seifert
• Analytical Sciences
  High-throughput Live Cell Imaging and Analysis for Temporal Reaction of G Protein-coupled Receptor Based on Split Luciferase Fragment Complementation
  M. Hattori and T. Ozawa
• Naunyn-Schmiedeberg's Archives of Pharmacology
  Structure-bias relationships for fenoterol stereoisomers in six molecular and cellular assays at the β2-adrenoceptor.
  M.T. Reinartz, S. Kälble, T. Littmann, T. Ozawa, S. Dove, V. Kaever, I.W. Wainer, R. Seifert
• RSC Advances
  Bioluminescent Tools for the Analysis of G-Protein-Coupled Receptor and Arrestin Interactions
  M. Hattori and T. Ozawa
• Methods in Molecular Biology
  Cell-Based Assays and Animal Models for GPCR Drug Screening
  H. Takakura, M. Hattori, M. Tanaka and T. Ozawa

2014

• Analytical Sciences
  Split Luciferase Complementation for Analysis of Intracellular Signaling
  M. Hattori and T. Ozawa

2013

• Molecular BioSystems
  Analysis of temporal patterns of GPCR–β-arrestin interactions using split luciferase-fragment complementation
  M. Hattori, M. Tanaka, H. Takakura, K, Aoki, K. Miura, T. Anzai and T. Ozawa

2012

• ACS Chemical Biology
  Visualization and Quantitative Analysis of G Protein-Coupled Receptor – β-Arrestin Interaction in Single Cells and Specific Organs of Living Mice Using Split Luciferase Complementation.
  H. Takakura, M. Hattori, M. Takeuchi and T. Ozawa

2011

• Pharmaceuticals,
  Dual-Color Bioluminescence Analysis for Quantitatively Monitoring G-Protein-Coupled Receptor and β-Arrestin Interactions.
  A.K.M. Kafi, M. Hattori and T. Ozawa

2010

• Analytical Chemistry
  Rapid and high-sensitivity cell-based assays of protein–protein interactions using split click beetle luciferase complementation: An approach to the study of G protein-coupled receptors
  N. Misawa, A.K.M. Kafi, M. Hattori, K. Miura, K. Masuda and T. Ozawa